Patents Assigned to UNIVERSITÄT BASEL
-
Patent number: 12208145Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.Type: GrantFiled: February 21, 2023Date of Patent: January 28, 2025Assignees: Universität Basel, Paul Scherrer InstituteInventors: Cristina Müller, Roger Schibli, Nicholas Philip Van Der Meulen, Francesca Borgna, Damian Wild, Melpomeni Fani
-
Publication number: 20250018067Abstract: The invention relates to a hafnium (IV) oxide (HfO2) nanoparticle nanocrystal comprising or having a diameter equal or less than (?) 15 nm, stabilized by a plurality of dispersant molecules attached to its surface. The dispersant molecules comprise of a catechol or gallol surface adsorption moiety and an oligo (ethyleneglycol) moiety. The invention further relates to a composition of such nanoparticles in stable colloidal suspension at physiological pH, and the use of the composition in medical treatment and diagnostic applications, particularly to enhance radiotherapy and as an X ray contrast agent. In yet another aspect, the invention provides a method for manufacturing compositions and nanoparticles according to the invention.Type: ApplicationFiled: November 23, 2022Publication date: January 16, 2025Applicants: UNIVERSITÄT BASEL, UNIVERSITEIT GENTInventors: Loren DEBLOCK, Jonathan DE ROO
-
Patent number: 12196740Abstract: The invention relates to a method for classifying a tissue sample obtained from mammary carcinoma. The method comprises determining a stiffness value for each of a plurality of points on said tissue sample, resulting in a stiffness distribution, and assigning said sample to a breast cancer subtype and nodal status based on said stiffness distribution.Type: GrantFiled: June 26, 2023Date of Patent: January 14, 2025Assignee: UNIVERSITÄT BASELInventors: Marija Plodinec, Ellen Obermann, Philipp Oertle, Christian Räz
-
Publication number: 20240344031Abstract: A mesenchymal stem/stromal (MSC) cell line, in particular a human mesenchymal stem cell (hMSC), capable of chondrogenic differentiation when cultured in a chondrogenic medium, comprising a first transgene comprising a first nucleic acid sequence encoding for a preferably mammalian immortalizing enzyme under control of a first promoter sequence operable in said mesenchymal cell and a second transgene comprising a second nucleic acid sequence encoding a preferably mammalian bone morphogenic protein under control of a second promoter sequence operable in said mesenchymal cell.Type: ApplicationFiled: August 2, 2022Publication date: October 17, 2024Applicant: UNIVERSITÄT BASELInventors: Sebastien PIGEOT, Ivan MARTIN, Paul BOURGINE
-
Patent number: 12091670Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.Type: GrantFiled: December 3, 2020Date of Patent: September 17, 2024Assignee: Universitaet BaselInventors: Cécile Arrieumerlou, Simon Ittig
-
Publication number: 20240299582Abstract: The present invention relates to adenovirus-associated virus comprising an influenza-derived neuraminidase transgene, used alone or together with an immune checkpoint inhibitor to treat a patient diagnosed with a solid cancer.Type: ApplicationFiled: February 18, 2022Publication date: September 12, 2024Applicant: UNIVERSITÄT BASELInventors: Heinz LÄUBLI, Natalia RODRIGUES MANTUANO
-
Publication number: 20240241099Abstract: The invention relates to a method of identifying selective covalently binding inhibitors by using a reversibly inhibiting scaffolds modified by a warhead comprising a fast-reacting Michael acceptor moiety and a linker of different length, determining kinact, and replacing the warhead of the covalently binding inhibitor with the highest kinact by a warhead comprising a moderately reacting Michael acceptor.Type: ApplicationFiled: April 9, 2022Publication date: July 18, 2024Applicant: UNIVERSITÄT BASELInventors: Chiara BORSARI, Matthias WYMANN
-
Publication number: 20240226540Abstract: A novel ultra-thin neural implant (1) is provided that is based on a cellulose thin film (4) featuring an array (2) of electrodes (3). Due to the use of cellulose as the base material, the implant (1) can be safely handled during a micro-surgery, despite its high softness and conformability. Such an implant (1) may be useful in numerous applications ranging from electrical stimulation in neural prostheses, electro-stimulated regeneration of neural tissue to accurate recording of nerve signals. The robustness of the implant (1) results from a woven fabric (5) that is integrated in the cellulose carrier thin film (4). Several approaches for enhancing the tissue compatibility of the implant (1) are also provided.Type: ApplicationFiled: May 6, 2022Publication date: July 11, 2024Applicant: Universität Basel Vizerektorat ForschungInventors: Bekim OSMANI, Tino TÖPPER, Bert MÜLLER, Carina LUCHSINGER SALINAS, Raphael GUZMAN, Alois HOPF, Mahyar JOODAKI
-
Publication number: 20240217960Abstract: Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP-binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads), targeting a solvent exposed cysteine at >10 ? from the core reversible inhibitor. A variety of novel linkers have been designed and used to link the warhead with the reversible scaffold. We disclose a novel chemical space for drug-like covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The invention relates to novel covalent inhibitors showing higher in vitro affinity, cellular potency and improved metabolic stability (rat liver microsomes).Type: ApplicationFiled: April 9, 2022Publication date: July 4, 2024Applicant: UNIVERSITÄT BASELInventors: Matthias WYMANN, Chiara BORSARI
-
Publication number: 20240208957Abstract: Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads) and behaving as reversible and irreversible covalent inhibitors. Linkers have been introduced to target a solvent exposed, distal cysteine at >10 ? from the core reversible inhibitor. Different exit vectors have been investigated to modulate inhibitor intrinsic reactivity and efficiency in covalent bond formation. We disclose novel, optimized covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The compounds of the invention could be exploited as therapeutic agents and chemical probes useful for the investigation of the role of PI3K isoforms in cancer and metabolism, and for treatment of PI3K?-driven cancers and malformations.Type: ApplicationFiled: April 9, 2022Publication date: June 27, 2024Applicant: UNIVERSITÄT BASELInventors: Chiara BORSARI, Matthias WYMANN
-
Patent number: 11992467Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.Type: GrantFiled: February 24, 2022Date of Patent: May 28, 2024Assignees: Universitaet Basel, Eth ZuerichInventors: Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
-
Patent number: 11982580Abstract: For improving the sensitivity, lifetime and energy consumption of a dielectric elastomer transducer (1) to be used as a sensor, it is suggested that a dielectric layer (3) enclosed by two electrodes (2) of the transducer (1) includes a nanoscale volume of a fluid (15) such that the dielectric layer (3) is rendered compressible and/or displaceable out of a volume enclosed by the two electrodes (2). The advantage of such a design is that, although the dielectric layer (3) and possible buffer layers (4) separating the electrodes (2) from the dielectric layer (3) may all have thicknesses in the order of a few ?m or even in the sub-?m range, the transducer (1) is rendered highly compliant due to the movability of the fluid (15). In consequence, a large nominal capacitance of the transducer (1) as well as a large relative capacitance change (up to twenty times that of the nominal capacitance) can be achieved in conjunction with a very high sensitivity.Type: GrantFiled: March 1, 2019Date of Patent: May 14, 2024Assignee: Universität Basel Vizerektorat ForschungInventors: Tino Topper, Bekim Osmani, Bert Mueller
-
Patent number: 11904051Abstract: A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress.Type: GrantFiled: January 31, 2019Date of Patent: February 20, 2024Assignees: Universität Basel, Universität FreiburgInventors: Bert Müller, Andreas Zumbühl, Thomas Pfohl, Dennis Müller, Frederik Neuhaus, Radu Tanasescu, Till Saxer, Marzia Buscema, Sofiya Matviykiv, Gabriela Gerganova
-
Patent number: 11896707Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.Type: GrantFiled: December 10, 2019Date of Patent: February 13, 2024Assignees: ETH Zurich, Universität BaselInventors: Michael Detmar, Epameinondas Gousopoulos, Olivier Potterat, Jihye Kim, Adriana Sliwa-Primorac, Antonia Elisabeth Schantl, Maria Teresa Faleschini, Matthias Hamburger
-
Patent number: 11878972Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (iii) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkType: GrantFiled: December 17, 2020Date of Patent: January 23, 2024Assignees: TORQUR AG, UNIVERSITÄT BASELInventors: Denise Rageot, Paul Hebeisen, Florent Beaufils, Doriano Fabbro, Petra Hillmann-Wüllner, Hoa Huu Phuc Nguyen, Wolfgang Löscher, Claudia Brandt, Alexander Markus Sele
-
Publication number: 20240010682Abstract: The present invention relates to a hemostatic elastin-like polypeptide comprising a glutamine embedded in a Q-block sequence and, optionally, a lysine embedded in a K-block sequence. Under physiological setting, the Q-block sequence and the K-block sequence are recognized by human transglutaminase factor XIIIa and crosslinked with fibrin networks. The present invention also relates to the medical use of the polypeptide, to a nucleic acid sequence encoding the polypeptide, to an expression vector comprising the nucleic acid sequence, and to a cell comprising the nucleic acid sequence or the expression vector.Type: ApplicationFiled: August 17, 2021Publication date: January 11, 2024Applicant: UNIVERSITÄT BASELInventors: Michael Adam NASH, Ivan UROSEV
-
Publication number: 20240002465Abstract: Described herein is a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.Type: ApplicationFiled: July 17, 2023Publication date: January 4, 2024Applicant: UNIVERSITÄT BASELInventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
-
Patent number: 11807676Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.Type: GrantFiled: March 7, 2022Date of Patent: November 7, 2023Assignees: UNIVERSITÄT ZÜRICH, UNIVERSITÄT BASELInventors: Osiris Marroquin Belaunzaran, Christoph Renner
-
Publication number: 20230353350Abstract: The invention relates to a method for device-independent quantum key generation and distribution between a first and a second receiver, the method comprising the steps of: a) Generating an entangled information pair, comprising two entangled quantum moieties that have at least one quantum state entangled with each other, such as a polarization, b) Transmitting a first entangled quantum moiety of the two entangled quantum moieties to the first receiver (A) and a second entangled quantum moiety of the two entangled quantum moieties to the second receiver (B), and measuring the quantum states of the entangled moieties with a set of selected detection settings chosen randomly at each receiver c) In a modification step, assigning each measurement value b1 measured with a detection setting B1 a complementary value b 1 ? according to a noise-probability p, wherein the noise-probability p is larger than 0 and lower than 1, such that a modified plurality of measurement values b 1 ˜ is obtainedType: ApplicationFiled: May 12, 2021Publication date: November 2, 2023Applicants: ETH ZURICH, UNIVERSITÄT BASELInventors: Melvyn HO, Pavel SEKATSKI, Jean-Daniel BANCAL, Nicolas SANGOUARD, Ernest TAN, Renato RENNER
-
Publication number: 20230344201Abstract: The present invention relates to a single photon source, comprising: a microcavity arranged between a concave first minor and a semiconductor heterostructure forming a planar second minor, wherein the microcavity supports an optical mode, a quantum dot embedded in the semiconductor heterostructure and facing the first minor, and a laser light source configured to provide laser light in the microcavity to excite the quantum dot to emit single photons exiting the microcavity.Type: ApplicationFiled: July 15, 2021Publication date: October 26, 2023Applicant: UNIVERSITÄT BASELInventors: Richard J. WARBURTON, Alisa JAVADI, Daniel NAJER, Natasha TOMM